Advertisement

Ads Placeholder
Loading...

Valneva SE

VLAP.PAEURONEXT
Healthcare
Biotechnology
0.07
0.00(0.00%)
U.S. Market opens in 54h 38m

Valneva SE Fundamental Analysis

Valneva SE (VLAP.PA) shows weak financial fundamentals with a PE ratio of -4.08, profit margin of -65.95%, and ROE of -74.52%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio0.42
Current Ratio2.38

Areas of Concern

ROE-74.52%
Operating Margin-50.33%
We analyze VLAP.PA's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -142.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-142.7/100

We analyze VLAP.PA's fundamental strength across five key dimensions:

Efficiency Score

Weak

VLAP.PA struggles to generate sufficient returns from assets.

ROA > 10%
-28.88%

Valuation Score

Excellent

VLAP.PA trades at attractive valuation levels.

PE < 25
-4.08
PEG Ratio < 2
0.42

Growth Score

Weak

VLAP.PA faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

VLAP.PA shows balanced financial health with some risks.

Debt/Equity < 1
1.95
Current Ratio > 1
2.38

Profitability Score

Weak

VLAP.PA struggles to sustain strong margins.

ROE > 15%
-7451.81%
Net Margin ≥ 15%
-65.95%
Positive Free Cash Flow
N/A

Key Financial Metrics

Is VLAP.PA Expensive or Cheap?

P/E Ratio

VLAP.PA trades at -4.08 times earnings. This suggests potential undervaluation.

-4.08

PEG Ratio

When adjusting for growth, VLAP.PA's PEG of 0.42 indicates potential undervaluation.

0.42

Price to Book

The market values Valneva SE at 4.43 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

4.43

EV/EBITDA

Enterprise value stands at -5.41 times EBITDA. This is generally considered low.

-5.41

How Well Does VLAP.PA Make Money?

Net Profit Margin

For every $100 in sales, Valneva SE keeps $-65.95 as profit after all expenses.

-65.95%

Operating Margin

Core operations generate -50.33 in profit for every $100 in revenue, before interest and taxes.

-50.33%

ROE

Management delivers $-74.52 in profit for every $100 of shareholder equity.

-74.52%

ROA

Valneva SE generates $-28.88 in profit for every $100 in assets, demonstrating efficient asset deployment.

-28.88%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.43 in free cash annually.

$-0.43

FCF Yield

VLAP.PA converts -15.89% of its market value into free cash.

-15.89%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-4.08

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.42

vs 25 benchmark

P/B Ratio

Price to book value ratio

4.43

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.67

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.95

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.38

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.75

vs 25 benchmark

ROA

Return on assets percentage

-0.29

vs 25 benchmark

ROCE

Return on capital employed

-0.29

vs 25 benchmark

How VLAP.PA Stacks Against Its Sector Peers

MetricVLAP.PA ValueSector AveragePerformance
P/E Ratio-4.0828.45 Better (Cheaper)
ROE-74.52%763.00% Weak
Net Margin-65.95%-45265.00% (disorted) Weak
Debt/Equity1.950.34 Weak (High Leverage)
Current Ratio2.382795.60 Strong Liquidity
ROA-28.88%-16588.00% (disorted) Weak

VLAP.PA outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Valneva SE's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ